{"id":545962,"date":"2010-04-28T10:58:08","date_gmt":"2010-04-28T14:58:08","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=76307"},"modified":"2010-04-28T10:58:08","modified_gmt":"2010-04-28T14:58:08","slug":"spiration-borrows-6-5m","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/545962","title":{"rendered":"Spiration Borrows $6.5M"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/Devices\/\">Devices<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Spiration, the Redmond, WA-based maker of devices for lung disease, has raised $6.5 million in debt and options from a single investor, according to a regulatory <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1129684\/000118143110023101\/xslFormDX01\/primary_doc.xml\">filing<\/a>. The company <a href=\"http:\/\/www.xconomy.com\/seattle\/2009\/09\/30\/spiration-pulls-in-7m-debt-financing-for-device-to-treat-lung-diseases\/\">borrowed $7 million last September<\/a> from its partner, Olympus Medical Systems. Spiration&#8217;s IBV valve device is designed to cut off air flow to diseased parts of the lung, where air gets trapped in patients with emphysema.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/04\/28\/spiration-borrows-6-5m\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Spiration%20Borrows%20$6.5M%20http:\/\/xconomy.com\/?p=76307\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/04\/28\/spiration-borrows-6-5m\/&#038;t=Spiration%20Borrows%20$6.5M\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/04\/28\/spiration-borrows-6-5m\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Spiration+Borrows+%246.5M&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F04%2F28%2Fspiration-borrows-6-5m%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>UNDERWRITERS AND PARTNERS<br \/>\n\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 51\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=51' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=51&amp;cb=988' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 14\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=14' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=14&amp;cb=2' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 6\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=6' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=6&amp;cb=777' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 66\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=66' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=66&amp;cb=149' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 253\n    [1] => 98\n    [2] => 108\n    [3] => 105\n    [4] => 112\n    [5] => 110\n    [6] => 101\n    [7] => 114\n    [8] => 82\n    [9] => 78\n    [10] => 80\n    [11] => 249\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=253' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=253&amp;cb=586' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 74\n    [1] => 76\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=74' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=74&amp;cb=171' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t\t<!-- ad options: Array\n(\n    [0] => 169\n)\n1 --><br \/>\n\t\t\t\t<a href='http:\/\/d.xconomy.com\/ck.php?bannerid=169' ><br \/>\n\t\t\t\t<img src='http:\/\/d.xconomy.com\/avw.php?bannerid=169&amp;cb=655' border='0' alt='' \/><\/a><br \/>\n\t\t\t\t\t\t\t\t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=754418552321df45ebf048b712e672f3&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=754418552321df45ebf048b712e672f3&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/ib.adnxs.com\/seg?add=24595&#038;t=2\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/d8gP8GLZB4RdaQtnK39FCI8E9As\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/d8gP8GLZB4RdaQtnK39FCI8E9As\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/d8gP8GLZB4RdaQtnK39FCI8E9As\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/d8gP8GLZB4RdaQtnK39FCI8E9As\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/Dy5J4l_F-BM\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Devices, deals Luke Timmerman wrote: Spiration, the Redmond, WA-based maker of devices for lung disease, has raised $6.5 million in debt and options from a single investor, according to a regulatory filing. The company borrowed $7 million last September from its partner, Olympus Medical Systems. Spiration&#8217;s IBV valve device is designed to cut off [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-545962","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/545962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=545962"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/545962\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=545962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=545962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=545962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}